SI1093815T1 - Oral 2-methyl-thieno-benzodiazepine formulation - Google Patents

Oral 2-methyl-thieno-benzodiazepine formulation

Info

Publication number
SI1093815T1
SI1093815T1 SI9630707T SI9630707T SI1093815T1 SI 1093815 T1 SI1093815 T1 SI 1093815T1 SI 9630707 T SI9630707 T SI 9630707T SI 9630707 T SI9630707 T SI 9630707T SI 1093815 T1 SI1093815 T1 SI 1093815T1
Authority
SI
Slovenia
Prior art keywords
thieno
oral
methyl
benzodiazepine formulation
benzodiazepine
Prior art date
Application number
SI9630707T
Other languages
English (en)
Slovenian (sl)
Inventor
George Randall Cochran
Tommy Clifford Morris
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1093815(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI1093815T1 publication Critical patent/SI1093815T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI9630707T 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation SI1093815T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24
PCT/US1996/003918 WO1996029995A1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation

Publications (1)

Publication Number Publication Date
SI1093815T1 true SI1093815T1 (en) 2005-06-30

Family

ID=23624847

Family Applications (3)

Application Number Title Priority Date Filing Date
SI9630707T SI1093815T1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation
SI9620041A SI9620041A (sl) 1995-03-24 1996-03-22 Oralna formulacija 2-metil-tieno-benzodiazepina
SI9630404T SI0733367T1 (en) 1995-03-24 1996-03-22 Oral olanzapine formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI9620041A SI9620041A (sl) 1995-03-24 1996-03-22 Oralna formulacija 2-metil-tieno-benzodiazepina
SI9630404T SI0733367T1 (en) 1995-03-24 1996-03-22 Oral olanzapine formulation

Country Status (46)

Country Link
US (4) US5919485A (lv)
EP (2) EP0733367B1 (lv)
JP (1) JPH11502848A (lv)
KR (1) KR100408172B1 (lv)
CN (1) CN1178662C (lv)
AP (1) AP679A (lv)
AR (2) AR001405A1 (lv)
AT (3) ATE206924T1 (lv)
AU (1) AU696601B2 (lv)
BG (1) BG62594B1 (lv)
BR (1) BR9607791A (lv)
CA (1) CA2216372C (lv)
CH (1) CH691217A5 (lv)
CO (1) CO4700474A1 (lv)
CR (1) CR5278A (lv)
CZ (1) CZ296007B6 (lv)
DE (3) DE19681287T1 (lv)
DK (3) DK0733367T3 (lv)
EA (1) EA000938B1 (lv)
EE (1) EE03551B1 (lv)
EG (1) EG24077A (lv)
ES (2) ES2232379T3 (lv)
FI (1) FI973749A (lv)
GB (1) GB2313783B (lv)
HU (1) HU225269B1 (lv)
IL (1) IL117611A (lv)
IS (1) IS1903B (lv)
LT (1) LT4350B (lv)
LU (1) LU90115B1 (lv)
LV (1) LV11983B (lv)
MY (1) MY113440A (lv)
NO (1) NO320388B1 (lv)
NZ (1) NZ306111A (lv)
OA (1) OA10511A (lv)
PE (1) PE44997A1 (lv)
PL (1) PL188316B1 (lv)
PT (2) PT733367E (lv)
RO (1) RO118370B1 (lv)
SE (1) SE9703206L (lv)
SI (3) SI1093815T1 (lv)
SK (1) SK283745B6 (lv)
TR (1) TR199701018T1 (lv)
TW (1) TW426526B (lv)
UA (1) UA44766C2 (lv)
WO (1) WO1996029995A1 (lv)
ZA (1) ZA962338B (lv)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7029112B2 (en) * 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
EP1670441A4 (en) * 2003-10-07 2012-05-02 Andrx Pharmaceuticals Llc FAST RESOLUTION FORMULATION
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20060240101A1 (en) * 2005-04-22 2006-10-26 Shubha Chungi Orally disintegrating pharmaceutical tablet formulations of olanzapine
JP4938005B2 (ja) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
JP4938006B2 (ja) * 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
DK2246051T3 (da) * 2008-01-31 2014-01-13 Kyorin Seiyaku Kk Fremgangsmåde til fremstilling af oralt sig hurtigt opløsende tablet omfattende imidafenacin som aktiv bestanddel
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
GB2473981B (en) * 2009-03-25 2012-02-22 Caitin Inc Thermodynamic cycle for cooling a working fluid
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
CN110709061B (zh) * 2017-06-02 2023-09-08 Xeris药物公司 抗沉淀的小分子药物制剂
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
DE69329887T2 (de) * 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
HU225269B1 (en) 2006-08-28
TW426526B (en) 2001-03-21
DK173323B1 (da) 2000-07-24
CO4700474A1 (es) 1998-12-29
CZ296007B6 (cs) 2005-12-14
SI0733367T1 (en) 2002-06-30
AT405606B (de) 1999-10-25
AP679A (en) 1998-09-28
IS4565A (is) 1997-09-22
US6190698B1 (en) 2001-02-20
DE69615887T2 (de) 2002-04-11
PE44997A1 (es) 1997-10-23
CA2216372C (en) 2007-11-20
FI973749A0 (fi) 1997-09-22
KR19980703189A (ko) 1998-10-15
ATE206924T1 (de) 2001-11-15
BG101901A (en) 1998-10-30
ES2164837T3 (es) 2002-03-01
AU5428096A (en) 1996-10-16
ATA902296A (de) 1999-02-15
CN1178662C (zh) 2004-12-08
DE69634053T2 (de) 2005-12-22
TR199701018T1 (xx) 1998-01-21
US6780433B2 (en) 2004-08-24
CN1179102A (zh) 1998-04-15
LT4350B (lt) 1998-05-25
EP0733367B1 (en) 2001-10-17
SE9703206D0 (sv) 1997-09-05
US20010018071A1 (en) 2001-08-30
NO974363D0 (no) 1997-09-22
EA000938B1 (ru) 2000-06-26
EP1093815B1 (en) 2004-12-15
CZ300197A3 (en) 1997-12-17
PT733367E (pt) 2002-03-28
DK0733367T3 (da) 2001-11-26
NZ306111A (en) 1999-02-25
CA2216372A1 (en) 1996-10-03
BR9607791A (pt) 1998-07-07
ES2232379T3 (es) 2005-06-01
FI973749A (fi) 1997-09-22
EE03551B1 (et) 2001-12-17
NO320388B1 (no) 2005-11-28
JPH11502848A (ja) 1999-03-09
EP1093815A1 (en) 2001-04-25
AU696601B2 (en) 1998-09-17
LT97149A (en) 1998-01-26
IL117611A (en) 2002-05-23
IS1903B (is) 2003-11-20
SI9620041A (sl) 1998-06-30
PT1093815E (pt) 2005-03-31
MY113440A (en) 2002-02-28
NO974363L (no) 1997-11-17
PL188316B1 (pl) 2005-01-31
UA44766C2 (uk) 2002-03-15
MX9707186A (es) 1997-11-29
US20050085462A1 (en) 2005-04-21
EG24077A (en) 2008-05-11
LV11983A (lv) 1998-03-20
LU90115B1 (fr) 1997-09-10
GB2313783B (en) 1998-11-18
DE19681287T1 (de) 1998-03-19
AP9701064A0 (en) 1997-10-31
US5919485A (en) 1999-07-06
SE9703206L (sv) 1997-09-05
ZA962338B (en) 1997-09-22
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
DE69634053D1 (de) 2005-01-20
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
CH691217A5 (de) 2001-05-31
EE9700328A (et) 1998-06-15
BG62594B1 (bg) 2000-03-31
OA10511A (en) 2002-04-24
WO1996029995A1 (en) 1996-10-03
DK109097A (da) 1997-11-12
DE69615887D1 (de) 2001-11-22
LV11983B (lv) 1998-07-20
GB2313783A (en) 1997-12-10
EA199700260A1 (ru) 1998-02-26
HUP9800410A2 (hu) 1998-07-28
CR5278A (es) 1996-07-04
IL117611A0 (en) 1996-07-23
RO118370B1 (ro) 2003-05-30
GB9719817D0 (en) 1997-11-19
HUP9800410A3 (en) 2000-01-28
DK1093815T3 (da) 2005-04-25
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
AR001405A1 (es) 1997-10-22
US7229643B2 (en) 2007-06-12
AR002720A1 (es) 1998-04-29

Similar Documents

Publication Publication Date Title
EG24077A (en) Oral 2-methyl-thieno-benzodiazepine formulation
EG23826A (en) Pharmaceutical formulations
PL322136A1 (en) Oral compositions
GB9519363D0 (en) Pharmaceutical formulation
AP9600883A0 (en) Pharmaceutical formulations
GB9514842D0 (en) Novel formulation
EP0862431A4 (en) PHARMACEUTICAL PREPARATION
GB9513694D0 (en) Oral compositions
GB9515597D0 (en) Oral compositions
GB9523566D0 (en) Pharmaceutical formulation
PL321282A1 (en) Oral compositions
ZA96526B (en) Novel pharmaceutical formulation
HUP9801706A3 (en) Oral compositions
GB9509291D0 (en) Formulations
ZA96392B (en) Pharmaceutical formulations
HU9602732D0 (en) Lanperisone formulation
GB2292886B (en) Oral hygiene formulation
GB9500978D0 (en) Pharmaceutical formulations
GB9510391D0 (en) Oral compositions
GB9513693D0 (en) Oral compositions
GB9508684D0 (en) Novel formulation
GB9508144D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9510349D0 (en) Formulations
GB9525386D0 (en) Pharmaceutical formulation